MX2019001186A - Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion. - Google Patents

Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion.

Info

Publication number
MX2019001186A
MX2019001186A MX2019001186A MX2019001186A MX2019001186A MX 2019001186 A MX2019001186 A MX 2019001186A MX 2019001186 A MX2019001186 A MX 2019001186A MX 2019001186 A MX2019001186 A MX 2019001186A MX 2019001186 A MX2019001186 A MX 2019001186A
Authority
MX
Mexico
Prior art keywords
methods
replication competent
assessing
absence
retrovirus
Prior art date
Application number
MX2019001186A
Other languages
English (en)
Inventor
Adin Bianchi Allison
Berry Ruth
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2019001186A publication Critical patent/MX2019001186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses

Abstract

Se proporcionan métodos para detectar retrovirus capaces de replicación en una muestra que contiene una célula transducida con una partícula de vector viral que codifica una molécula recombinante y/o heteróloga, por ejemplo, un producto génico heterólogo. Los métodos pueden incluir evaluar la transcripción de uno o más genes objetivo, tales como los genes virales, que se expresan en un retrovirus, pero no se expresan en la partícula de vector viral. Se puede determinar que el retrovirus capaz de replicación está presente si los niveles de ARN de uno o más genes objetivo son más altos que un valor de referencia, que puede medirse directa o indirectamente, incluyendo una muestra de control positivo que contiene ARN del gen objetivo respectivo en un nivel conocido y/o en o por encima del límite de detección del ensayo.
MX2019001186A 2016-07-29 2017-07-28 Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion. MX2019001186A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369024P 2016-07-29 2016-07-29
US201762448954P 2017-01-20 2017-01-20
PCT/US2017/044550 WO2018023094A1 (en) 2016-07-29 2017-07-28 Methods for assessing the presence or absence of replication competent virus

Publications (1)

Publication Number Publication Date
MX2019001186A true MX2019001186A (es) 2019-08-29

Family

ID=59656184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001186A MX2019001186A (es) 2016-07-29 2017-07-28 Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion.

Country Status (10)

Country Link
US (2) US11421287B2 (es)
EP (1) EP3491152B1 (es)
JP (2) JP2019521695A (es)
CN (1) CN109804089A (es)
AU (1) AU2017301881A1 (es)
CA (1) CA3031994A1 (es)
ES (1) ES2926513T3 (es)
MA (1) MA45783A (es)
MX (1) MX2019001186A (es)
WO (1) WO2018023094A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021511802A (ja) * 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬
EP3793570A2 (en) 2018-05-15 2021-03-24 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
US20230043255A1 (en) 2018-11-14 2023-02-09 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
CN111910015A (zh) * 2019-05-08 2020-11-10 深圳宾德生物技术有限公司 一种检测复制型慢病毒的探针、引物对、荧光定量pcr试剂盒及方法
WO2021046143A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
CN111647576B (zh) * 2020-06-24 2021-02-09 南京诺唯赞生物科技股份有限公司 一种热稳定性逆转录酶突变体及其应用
CN115852064A (zh) * 2020-09-30 2023-03-28 浙江大学 用于检测hbv基因t216c突变位点的引物和探针
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
CN112877474A (zh) * 2021-02-19 2021-06-01 北京鼎成肽源生物技术有限公司 一种检测慢病毒介导的基因修饰细胞中复制型病毒的引物组、试剂盒及方法
CN113264989A (zh) * 2021-05-17 2021-08-17 吉林大学 一种h9n2亚型禽流感嵌合病毒样颗粒制备方法及应用
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
CN113699278A (zh) * 2021-09-17 2021-11-26 深圳因诺免疫有限公司 一种基于q-PCR法检测复制型逆转录病毒的引物、试剂盒及检测方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4996143A (en) 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
CA1339684C (en) 1988-05-17 1998-02-24 Peter H. Quail Plant ubquitin promoter system
DE68919715T2 (de) 1988-12-28 1995-04-06 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
DE69231853T2 (de) 1991-11-07 2001-09-13 Nanotronics Inc Hybridisierung von mit chromophoren und fluorophoren konjugierten polynukleotiden zur erzeugung eines donor-zu-donor energietransfersystems
WO1994019491A1 (en) 1993-02-17 1994-09-01 Genetic Therapy, Inc. Detection of replication competent viruses
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
ATE428801T1 (de) 1996-06-04 2009-05-15 Univ Utah Res Found Überwachung der hybridisierung während pcr
DE69738605T2 (de) 1996-06-04 2009-04-30 University Of Utah Research Foundation, Salt Lake City Behälter zum Durchführen und Beobachten biologischer Prozesse
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6303293B1 (en) * 1999-02-02 2001-10-16 Ortho-Clinical Diagnostics, Inc. Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof
AU6076600A (en) 1999-07-09 2001-01-30 Tranzyme, Inc. Retroviral recombination assays and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP5213297B2 (ja) 2000-08-11 2013-06-19 ユニバーシティ オブ ユタ リサーチ ファウンデーション 単一ラベルオリゴヌクレオチド・プローブ
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
US6712612B1 (en) * 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
KR100440852B1 (ko) 2001-05-10 2004-07-19 주식회사 바이로메드 레트로바이러스에 특이적인 올리고뉴클레오티드 프라이머및 이를 이용한 레트로바이러스 농도 측정방법
ITCZ20020002A1 (it) 2002-04-11 2003-10-13 Parco Scient E Tecnologico Del Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1534847B1 (en) * 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2007008309A2 (en) * 2005-06-01 2007-01-18 Children's Hospital Medical Center Stem and progenitor cell expansion by evi, evi-like genes and setbp1
US20090028836A1 (en) * 2005-06-01 2009-01-29 Kalle Christof Von Stem and progenitor cell expansion by evi, evi-like genes and setbp1
US7741467B2 (en) 2005-10-05 2010-06-22 Roche Molecular Systems, Inc. Non-fluorescent energy transfer
AU2008233051B2 (en) 2007-03-30 2014-04-10 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
EP3342872A1 (en) 2007-12-11 2018-07-04 The University of North Carolina at Chapel Hill Polypurine tract modified retroviral vectors
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US20100184015A1 (en) * 2008-12-23 2010-07-22 Silverman Robert H Method for detection of xmrv
CN102154368B (zh) * 2010-02-11 2015-01-21 上海比昂生物医药科技有限公司 一种组织特异性兼可调控性慢病毒基因表达载体
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
BR112013024395B1 (pt) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
ES2774160T3 (es) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
ES2733525T3 (es) 2012-07-13 2019-11-29 Univ Pennsylvania Métodos para evaluar la adecuación de los linfocitos T transducidos para su administración
AU2013305838A1 (en) 2012-08-20 2015-02-26 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9944998B2 (en) 2013-07-25 2018-04-17 Bio-Rad Laboratories, Inc. Genetic assays
CA2935929C (en) 2014-01-10 2022-02-22 Sirion Biotech Gmbh Pseudotyped lentiviral vectors
KR20160113295A (ko) * 2014-02-04 2016-09-28 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
JP2021511802A (ja) 2018-01-31 2021-05-13 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法および試薬

Also Published As

Publication number Publication date
EP3491152B1 (en) 2022-06-29
US20200056249A1 (en) 2020-02-20
JP2022130714A (ja) 2022-09-06
US20230091137A1 (en) 2023-03-23
MA45783A (fr) 2019-06-05
AU2017301881A1 (en) 2019-02-07
EP3491152A1 (en) 2019-06-05
WO2018023094A1 (en) 2018-02-01
JP2019521695A (ja) 2019-08-08
ES2926513T3 (es) 2022-10-26
US11421287B2 (en) 2022-08-23
CA3031994A1 (en) 2018-02-01
CN109804089A (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
MX2019001186A (es) Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion.
TW201614073A (en) Non-replicative transduction particles and transduction particle-based reporter systems
MX360560B (es) Partículas de transducción no replicativas y sistemas indicadores a base de partículas de transducción.
Robb et al. Splicing of influenza A virus NS1 mRNA is independent of the viral NS1 protein
Liao et al. Ubiquitination and deubiquitination of NP protein regulates influenza A virus RNA replication
PH12019500316A1 (en) Methods for detecting aav
Kirui et al. Ubiquitination upregulates influenza virus polymerase function
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
EP4180531A3 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
Samad et al. B23/nucleophosmin is involved in regulation of adenovirus chromatin structure at late infection stages, but not in virus replication and transcription
MX354822B (es) Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus.
EA201791630A1 (ru) Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
WO2018017747A3 (en) Oncolytic viruses targeting stat3
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EA201890351A1 (ru) Рекомбинантный orf-вирусный вектор
MX2016013584A (es) Parvovirus porcino.
Chou et al. The ORF8 protein of SARS-CoV-2 modulates the spike protein and its implications in viral transmission
Tani et al. Development of cytotoxicity-sensitive human cells using overexpression of long non-coding RNAs
Biquand et al. Comparative profiling of ubiquitin proteasome system interplay with influenza A virus PB2 polymerase protein recapitulating virus evolution in humans
Yang et al. RanBPM regulates Zta-mediated transcriptional activity in Epstein–Barr virus
MX2021010169A (es) Transactivadores de dominios de union a adn y usos de estos.
MX2019014661A (es) Variantes de b4galt1 y usos de estas.
Muller et al. CCHCR1 interacts specifically with the E2 protein of human papillomavirus type 16 on a surface overlapping BRD4 binding
Ma et al. Impact of the segment-specific region of the 3′-untranslated region of the influenza A virus PB1 segment on protein expression